Blood Eosinophils and Exacerbations in Chronic Obstructive Pulmonary Disease: The Copenhagen General Population Study

Publikation: Bidrag til tidsskriftTidsskriftartikelfagfællebedømt

Standard

Blood Eosinophils and Exacerbations in Chronic Obstructive Pulmonary Disease : The Copenhagen General Population Study. / Vedel-Krogh, Signe; Nielsen, Sune F; Lange, Peter; Vestbo, Jørgen; Nordestgaard, Børge G.

I: American Journal of Respiratory and Critical Care Medicine, Bind 193, Nr. 9, 01.05.2016, s. 965-974.

Publikation: Bidrag til tidsskriftTidsskriftartikelfagfællebedømt

Harvard

Vedel-Krogh, S, Nielsen, SF, Lange, P, Vestbo, J & Nordestgaard, BG 2016, 'Blood Eosinophils and Exacerbations in Chronic Obstructive Pulmonary Disease: The Copenhagen General Population Study', American Journal of Respiratory and Critical Care Medicine, bind 193, nr. 9, s. 965-974. https://doi.org/10.1164/rccm.201509-1869OC

APA

Vedel-Krogh, S., Nielsen, S. F., Lange, P., Vestbo, J., & Nordestgaard, B. G. (2016). Blood Eosinophils and Exacerbations in Chronic Obstructive Pulmonary Disease: The Copenhagen General Population Study. American Journal of Respiratory and Critical Care Medicine, 193(9), 965-974. https://doi.org/10.1164/rccm.201509-1869OC

Vancouver

Vedel-Krogh S, Nielsen SF, Lange P, Vestbo J, Nordestgaard BG. Blood Eosinophils and Exacerbations in Chronic Obstructive Pulmonary Disease: The Copenhagen General Population Study. American Journal of Respiratory and Critical Care Medicine. 2016 maj 1;193(9):965-974. https://doi.org/10.1164/rccm.201509-1869OC

Author

Vedel-Krogh, Signe ; Nielsen, Sune F ; Lange, Peter ; Vestbo, Jørgen ; Nordestgaard, Børge G. / Blood Eosinophils and Exacerbations in Chronic Obstructive Pulmonary Disease : The Copenhagen General Population Study. I: American Journal of Respiratory and Critical Care Medicine. 2016 ; Bind 193, Nr. 9. s. 965-974.

Bibtex

@article{7ab60edefcb840c69cd9f4a38bdd90c7,
title = "Blood Eosinophils and Exacerbations in Chronic Obstructive Pulmonary Disease: The Copenhagen General Population Study",
abstract = "RATIONALE: Whether high blood eosinophils are associated with COPD exacerbations among individuals with COPD in the general population is largely unknown.OBJECTIVES: To test the hypothesis that high blood eosinophils predict COPD exacerbations.METHODS: Among 81,668 individuals from the Copenhagen General Population Study, we examined 7,225 with COPD based on spirometry. We recorded blood eosinophils at baseline and future COPD exacerbations longitudinally, defined as moderate (short-course treatment of systemic corticosteroids) or severe (hospitalization). We also assessed exacerbation risk in a subgroup of 203 COPD individuals with clinical COPD, defined as participants with ≥ 10 pack-years, FEV1 < 70% of predicted value and ≥ 1 moderate or severe exacerbation in the year prior to baseline.MEASUREMENTS AND MAIN RESULTS: During a median of 3.3 years of follow-up (range 0.03-8.1), 1,439 severe and 2,864 moderate COPD exacerbations were recorded. Among all participants with COPD, blood eosinophils above versus below 0.34∙10(9) cells/L had a multivariable adjusted incidence rate ratio of 1.76 (95%CI: 1.56-1.99) for severe exacerbations and of 1.15 (1.05-1.27) for moderate exacerbations. Corresponding values in those with clinical COPD were 3.21 (2.49-4.14) and 1.69 (1.40-2.04). In contrast, using a cut-point of 2% for blood eosinophils, the risk of exacerbations was only increased for severe exacerbations among individuals with clinical COPD but not in individuals from the broader population.CONCLUSIONS: Among individuals with COPD in the general population, increased blood eosinophil levels above 0.34∙10(9) cells/L were associated with a 1.76-fold increased risk of severe exacerbations.",
author = "Signe Vedel-Krogh and Nielsen, {Sune F} and Peter Lange and J{\o}rgen Vestbo and Nordestgaard, {B{\o}rge G}",
year = "2016",
month = may,
day = "1",
doi = "10.1164/rccm.201509-1869OC",
language = "English",
volume = "193",
pages = "965--974",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "9",

}

RIS

TY - JOUR

T1 - Blood Eosinophils and Exacerbations in Chronic Obstructive Pulmonary Disease

T2 - The Copenhagen General Population Study

AU - Vedel-Krogh, Signe

AU - Nielsen, Sune F

AU - Lange, Peter

AU - Vestbo, Jørgen

AU - Nordestgaard, Børge G

PY - 2016/5/1

Y1 - 2016/5/1

N2 - RATIONALE: Whether high blood eosinophils are associated with COPD exacerbations among individuals with COPD in the general population is largely unknown.OBJECTIVES: To test the hypothesis that high blood eosinophils predict COPD exacerbations.METHODS: Among 81,668 individuals from the Copenhagen General Population Study, we examined 7,225 with COPD based on spirometry. We recorded blood eosinophils at baseline and future COPD exacerbations longitudinally, defined as moderate (short-course treatment of systemic corticosteroids) or severe (hospitalization). We also assessed exacerbation risk in a subgroup of 203 COPD individuals with clinical COPD, defined as participants with ≥ 10 pack-years, FEV1 < 70% of predicted value and ≥ 1 moderate or severe exacerbation in the year prior to baseline.MEASUREMENTS AND MAIN RESULTS: During a median of 3.3 years of follow-up (range 0.03-8.1), 1,439 severe and 2,864 moderate COPD exacerbations were recorded. Among all participants with COPD, blood eosinophils above versus below 0.34∙10(9) cells/L had a multivariable adjusted incidence rate ratio of 1.76 (95%CI: 1.56-1.99) for severe exacerbations and of 1.15 (1.05-1.27) for moderate exacerbations. Corresponding values in those with clinical COPD were 3.21 (2.49-4.14) and 1.69 (1.40-2.04). In contrast, using a cut-point of 2% for blood eosinophils, the risk of exacerbations was only increased for severe exacerbations among individuals with clinical COPD but not in individuals from the broader population.CONCLUSIONS: Among individuals with COPD in the general population, increased blood eosinophil levels above 0.34∙10(9) cells/L were associated with a 1.76-fold increased risk of severe exacerbations.

AB - RATIONALE: Whether high blood eosinophils are associated with COPD exacerbations among individuals with COPD in the general population is largely unknown.OBJECTIVES: To test the hypothesis that high blood eosinophils predict COPD exacerbations.METHODS: Among 81,668 individuals from the Copenhagen General Population Study, we examined 7,225 with COPD based on spirometry. We recorded blood eosinophils at baseline and future COPD exacerbations longitudinally, defined as moderate (short-course treatment of systemic corticosteroids) or severe (hospitalization). We also assessed exacerbation risk in a subgroup of 203 COPD individuals with clinical COPD, defined as participants with ≥ 10 pack-years, FEV1 < 70% of predicted value and ≥ 1 moderate or severe exacerbation in the year prior to baseline.MEASUREMENTS AND MAIN RESULTS: During a median of 3.3 years of follow-up (range 0.03-8.1), 1,439 severe and 2,864 moderate COPD exacerbations were recorded. Among all participants with COPD, blood eosinophils above versus below 0.34∙10(9) cells/L had a multivariable adjusted incidence rate ratio of 1.76 (95%CI: 1.56-1.99) for severe exacerbations and of 1.15 (1.05-1.27) for moderate exacerbations. Corresponding values in those with clinical COPD were 3.21 (2.49-4.14) and 1.69 (1.40-2.04). In contrast, using a cut-point of 2% for blood eosinophils, the risk of exacerbations was only increased for severe exacerbations among individuals with clinical COPD but not in individuals from the broader population.CONCLUSIONS: Among individuals with COPD in the general population, increased blood eosinophil levels above 0.34∙10(9) cells/L were associated with a 1.76-fold increased risk of severe exacerbations.

U2 - 10.1164/rccm.201509-1869OC

DO - 10.1164/rccm.201509-1869OC

M3 - Journal article

C2 - 26641631

VL - 193

SP - 965

EP - 974

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 9

ER -

ID: 153787434